Table of Contents PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Market landscape • Market overview • Five forces analysis PART 06: Market segmentation by application • Global regenerative medicine market • Global next-generation antibodies market • Global next-generation insulin products market • Global next-generation recombinant coagulation factors market PART 07: Geographical segmentation • Next-generation biologics market in Americas • Next-generation biologics market in EMEA • Next-generation biologics market in APAC PART 08: Market drivers • Increase in demand for ADCs • Advanced technological innovations • Reimbursement support for next-generation biologics • Special regulatory drug designations for biologics PART 09: Impact of drivers PART 10: Market challenges • Complexities in manufacturing of biologics • Complicated regulatory framework • Difficulties in patient recruitment for conducting clinical trials, high cost, and failure rate in clinical trials • Critical ethical challenges in clinical trial design PART 11: Impact of drivers and challenges PART 12: Market trends • Focus on regenerative medicines • Focus on oral insulin therapies • Development of gene and cell therapy-based products • Emergence of targeted and combination therapies PART 13: Vendor landscape • Competitive scenario • Key news • Other prominent vendors PART 14: Key vendor analysis • Biogen • F. Hoffmann-La Roche • Novo Nordisk • Sanofi4 • Takeda Pharmaceuticals PART 15: Appendix • List of abbreviations PART 16: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Global next-generation biologics market Exhibit 03: Overview of next-generation biologics market 2016-2020 Exhibit 04: Key strategies in global next-generation biologics market Exhibit 05: Global next-generation biologics market snapshot: Developed and emerging markets 2015 Exhibit 06: Global next-generation biologics market 2015-2020 ($ billions) Exhibit 07: Opportunities faced by biologics industry today Exhibit 08: Five forces analysis Exhibit 09: Global next-generation biologics market segmentation by therapies Exhibit 10: Market share of next-generation biologics by application Exhibit 11: Market overview of global regenerative medicine market Exhibit 12: Sub-segmentation in regenerative medicine market Exhibit 13: Global regenerative medicine market 2015-2020 ($ billions) Exhibit 14: Funds from federal agencies for regenerative medicine research in 2014 ($ millions) Exhibit 15: Cell therapy overview Exhibit 16: Gene therapy products available in Europe Exhibit 17: R&D in tissue scaffold Exhibit 18: Opportunity analysis of global regenerative medicine market Exhibit 19: Market overview of next-generation antibodies Exhibit 20: Sub-segmentation in next-generation antibodies market Exhibit 21: Global next-generation antibodies market 2015-2020 ($ billions) Exhibit 22: Global next-generation antibodies market: Present and future scenario Exhibit 23: Opportunity analysis of global next-generation antibodies market Exhibit 24: Market overview of next-generation insulin products Exhibit 25: Factors affecting global next-generation insulin products market Exhibit 26: Global next-generation insulin products market 2015-2020 ($ millions) Exhibit 27: Opportunity analysis of global next-generation insulin products market Exhibit 28: Market overview of next-generation recombinant coagulation factors Exhibit 29: Global next-generation recombinant coagulation factors market 2015-2020 ($ billions) Exhibit 30: Opportunity analysis of global next-generation recombinant coagulation factors market Exhibit 31: Impact of factors affecting the market 2015 and 2020 Exhibit 32: Global next-generation biologics market: Segmentation by geography (2015-2020) Exhibit 33: Global next-generation biologics market segmentation by region: Market growth lifecycle analysis 2015 Exhibit 34: Overview of next-generation biologics market in Americas Exhibit 35: Next-generation biologics market in Americas 2015-2020 ($ billions) Exhibit 36: Stem cell research policies in Americas Exhibit 37: Overview of next-generation biologics market in EMEA Exhibit 38: Distribution of major cell therapy vendors in Europe 2011 Exhibit 39: Next-generation biologics market in EMEA 2015-2020 ($ billions) Exhibit 40: Stem cell research policies in EMEA Exhibit 41: Overview of next-generation biologics market in APAC Exhibit 42: Global next-generation biologics market revenue by geography 2015-2020 ($ billions) Exhibit 43: Key regenerative medicine market developments in Japan by global vendors 2015 Exhibit 44: Next-generation biologics market in APAC 2015-2020 ($ billions) Exhibit 45: Stem cell research policies in APAC Exhibit 46: ADC molecules currently under clinical trials Exhibit 47: Advances in ADCs technology Exhibit 48: Technologies used in next-generation biologics Exhibit 49: Breakdown of CIRM funding in various stem cell research funding in 2014 ($ billions) Exhibit 50: Active programs under CIRM in 2014 Exhibit 51: EC funding Exhibit 52: Some of special regulatory designations approved by US FDA Exhibit 53: Special regulatory designation approved by EU Exhibit 54: Impact of drivers Exhibit 55: Ethical issues that are faced by various institutes at different phases of cell therapy research Exhibit 56: Impact of drivers and challenges Exhibit 57: Impact of trends on global next-generation biologics market Exhibit 58: Some of the regenerative medicines under development for the treatment of various musculoskeletal disorders Exhibit 59: Planned clinical trials of iPS cell-based therapies Exhibit 60: Regenerative medicines for IBS under development Exhibit 61: Some of the mid- and late-stage pipeline products for regenerative medicine Exhibit 62: Oral insulin pipeline portfolio Exhibit 63: Gene therapies under development for hemophilia Exhibit 64: Geographical presence of key vendors Exhibit 65: Competitive scenario of global next-generation biologics market vendors 2015-2020 Exhibit 66: Biogen: Key highlights Exhibit 67: Biogen: Strength assessment Exhibit 68: Biogen: Strategy assessment Exhibit 69: Biogen: Opportunity assessment Exhibit 70: F. Hoffmann-La Roche: KADCYLA pipeline products Exhibit 71: F. Hoffmann-La Roche: Key highlights Exhibit 72: F. Hoffmann-La Roche: Strength assessment Exhibit 73: F. Hoffmann-La Roche: Strategy assessment Exhibit 74: F. Hoffmann-La Roche: Opportunity assessment Exhibit 75: Novo Nordisk: Highlights Exhibit 76: Novo Nordisk: Strength assessment Exhibit 77: Novo Nordisk: Strategy assessment Exhibit 78: Novo Nordisk: Opportunity assessment Exhibit 79: Sanofi: Highlights Exhibit 80: Sanofi: Strength assessment Exhibit 81: Sanofi: Strategy assessment Exhibit 82: Sanofi: Opportunity assessment Exhibit 83: Takeda Pharmaceuticals: Highlights Exhibit 84: Takeda Pharmaceuticals: Strength assessment Exhibit 85: Takeda Pharmaceuticals: Strategy assessment Exhibit 86: Takeda Pharmaceuticals: Opportunity assessment

Biogen, F. Hoffmann-La Roche, Novo Nordisk, Sanofi, Takeda Pharmaceuticals, Aastrom Biosciences, AbbVie, AbGenomics, Acologix, ADC Therapeutics, Adocia, Agensys, AlloCure, AlloSource, ALMAC Group, Alphatec Spine, Ambrx, Amorcyte, Argos Therapeutics, Astellas Pharma, AstraZeneca, Athersys, Avita Medical, Baxter, Bayer HealthCare, Bellicum Pharmaceuticals, BioCardia, Biocon, Biodel, BIOGENOMICS, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, Boehringer Ingelheim, BrainStorm Cell Therapeutics, Calimmune, Capricor, CARBOGEN AMCIS, Cell Medica, Celldex Therapeutics, Celyad, Cesca, CryoLife, CSL Behring, Cynata Therapeutics, Daiichi Sankyo, Dance Biopharm, Dendreon, Diasome Pharmaceuticals, DiscGenics, Endo Pharmaceuticals, Esperance Pharmaceuticals, Exsulin, Fate Therapeutics, Fibrocell Science, Formation Biologics, Forticell Bioscience, Fortress Biotech, Gamida Cell, GENEREX, Genmab, Geron, GlaxoSmithKline, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics, Immunogen, Integra LifeSciences, InVivo Therapeutics, ISTO Technologies, Juno Therapeutics, Juventas Therapeutics, Kairos Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MacroGenics, MannKind, MaxCyte, MedImmune, Medtronic, Mersana Therapeutics, Mesoblast, MiMedx, Nanofiber Solutions, Nanotope, Neuralstem, NewLink Genetics, NGM Biopharmaceuticals, Northwest Biotherapeutics, Novartis, NovaRx, Ocata Therapeutics, Opexa Therapeutics, Oramed Pharmaceuticals, Organovo, Orteq, Orthofix, Osiris Therapeutics, Osteotech, OXFORD BioTherapeutics, Pfizer, PhaseBio Pharmaceuticals, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, ReproCELL, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, STEMCELL Technologies, Stemcentrx, Stratatech, Synthon Biopharmaceuticals, TEI Biosciences, Tengion, Thermalin Diabetes, TiGenix, Tissue Genesis, TissueGene, Tolerion, VentriNova, Vericel, VeroScience, ViaCyte, VistaGen Therapeutics, vTv Therapeutics, Wockhardt, XOMA, Zimmer-Biomet, Zymeworks.